17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2. Target:HSP (e.g. HSP90) Pathway:Cytoskeletal Signaling MW:585.69